Condition (MeSH)
Mycobacterium avium-intracellulare Infection
ClinicalTrials.gov lists 66 trials for Mycobacterium avium-intracellulare Infection or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 18.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
66 of the 66 trials are tagged with Mycobacterium avium-intracellulare Infection itself; the rest are tagged with a narrower condition beneath it.
When did Mycobacterium avium-intracellulare Infection trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mycobacterium avium-intracellulare Infection trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 15 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Phase 4 | 4 |
| Not applicable | 17 |
| Observational | 11 |
How many Mycobacterium avium-intracellulare Infection trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 52 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mycobacterium avium-intracellulare Infection trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 18 |
| Pfizer | 6 |
| Pharmacia | 6 |
| Insmed Incorporated | 2 |
| Spero Therapeutics | 2 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Mycobacterium avium-intracellulare Infection? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Rifabutin | 13 |
| Clofazimine | 5 |
| Nelfinavir | 2 |
| ELC | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Azithromycin | 17 |
| Ethambutol Oral Product | 12 |
| Clarithromycin XL | 12 |
| Rifampicin | 3 |
| ALIS | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mycobacterium avium-intracellulare Infection trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Atypical mycobacterial infection | 6 | 1 |
| Pneumonia | 4 | 1 |
| Haemoptysis | 3 | 2 |
| Infective exacerbation of bronchiectasis | 3 | 2 |
| Acute respiratory failure | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Mycobacterium avium-intracellulare Infection? (84)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| OPTIMA: An Open-Label, Noncomparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection. | Annals of the American Thoracic Society | 2024 | Yes |
| Serum Cell-Free DNA-based Detection of <i>Mycobacterium avium</i> Complex Infection. | American journal of respiratory and critical care medicine | 2024 | Yes |
| Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study. | Respiratory investigation | 2024 | Yes |
| Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease. | Chest | 2023 | Yes |
| Exploring the role of point-of-care ultrasound for people with HIV in a resource affluent setting: A prospective observational study. | International journal of STD & AIDS | 2023 | Yes |
Showing 5 of 84 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.